Following the publication of the experimental study by Fraile B et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.” on Future Microbiology 2017; 12: 721-73 , the authors presented a new communication at the VII International Congress of Histology and Tissue Engineering. Santiago [...]
New partnership: Xilaplus® AF in Turkey Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF in Turkey. Xilaplus® AF is a Class IIa CE marked medical device specifically formulated for the control and reduction of diarrheal events of various etiologies. Xilaplus® AF acts [...]
Annamaria Staiano Italian Journal of Pediatrics 2017, 43(Suppl 1): A2 Diarrhoea in children still has a major impact on health-related social costs, affecting approximately 2 billion children younger than 5 years every year, and determining 2 million deaths, mostly in Africa and Asia. [1] According to WHO diarrhea consists in [...]
Ford et al. N Engl J Med 2017; 376:2566-78 New article in NEJM supports the role of increased intestinal permeability in the pathophysiology of IBS. Increased intestinal permeability and tight junctions alterations trigger an inflammatory reaction which alters visceral neuromuscular function, leading to IBS symptoms like abdominal pain and diarrhea [...]
European Association of Urology – London 25th – 27th March 2017. More than 10.300 total participants, coming from 113 countries all over the world. Out of around 10.000 delegates, mainly urologists, nearly 20% were residents. 200 exhibitors took part to the congress, thus adding further 2200 participants to the event. [...]
Barcelona, March 13, 2017 – Noventure and Riksförbundet för sexuell upplysning (RFSU), the Swedish Association for Sexuality Education, announce today that they have entered into an agreement by which RFSU will distribute Noventure’s Utipro® Plus in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With this agreement, Utipro Plus [...]
De Servi B et al. Future Microbiology. Published on line: 29 March 2016 Aim: To evaluate whether Utipro(®), a natural product approved to prevent urinary tract infections, protects intestinal epithelial cells from Escherichia coli adherence/intracellular invasion in vitro. Materials & Methods: Caco-2 and CacoGoblet(TM) cells were treated with Utipro (1.5 [...]
L. Bueno et al. UEG Journal – United European Gastroenterology Journal, Oct.2013: Vol. 1, Supl. 1; ISSN 2050-6406 (print) ISSN 2050-6414 (online) – Pags A75-A76 Introduction: Gelatine (GEL) stabilised by cross-linking with tannic acid (TA) forms gelatine tannate (GT). GT is approved as medical device for the oral treatment of diarrhoea [...]
Freli V. et al. Presented at GFHGHP 2012. Presented as oral communication at the 33rd edition of the Congress from the Groupe Francophone d’Hépato-Gastroentérologie et Nutrition Pédiatriques in Nantes, France, March 2012. Abstract: New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 1: filmforming effect. [...]
Kim YS, Ho SB. Curr Gastroenterol Rep. 2010 Oct;12(5):319-30 The mucus layer coating the gastrointestinal tract is the front line of innate host defense, largely because of the secretory products of intestinal goblet cells. Goblet cells synthesize secretory mucin glycoproteins (MUC2) and bioactive molecules such as epithelial membrane-bound mucins (MUC1, [...]